Insmed $INSM

Health Care · NASDAQ

$141.33
-3.13 (-2.17%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Sep 24, 2026, the first target we tracked for INSM.

Insmed (INSM) is trading down at $141.33 (-2.17%) on NASDAQ, as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.

Analyst price targets on INSM

Current price targets from 7 firms average $196, median $195, ranging from $172 to $220 — the average is 38% above the current $141. Each is tracked to its date and scored the same way a member's call is.

7 targets, newest first. Open a row for its source and scoring.

DateOct 29, 2026 FirmStifel RatingBuy · lowers Targetat $112 · $195 +75% Horizonby Oct 2027 StatusOpen

Entry price $112, the close nearest Oct 29, 2026, when the target was reported; the target is +75% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 29, 2027.

Source Stifel cuts Insmed stock price target to $195 on OpEx outlook Investing.com · Oct 29, 2026 · opens the publisher's site
Stifel lowered its price target on Insmed shares (NASDAQ:INSM) to $195 from $200 while maintaining a Buy rating on Thursday.
DateOct 27, 2026 FirmMizuho RatingOutperform · reiterates Targetat $95 · $195 +105% Horizonby Oct 2027 StatusOpen

Entry price $95, the close nearest Oct 27, 2026, when the target was reported; the target is +105% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 27, 2027.

Source H.C. Wainwright reiterates Insmed stock rating on pipeline progress Investing.com · Oct 27, 2026 · opens the publisher's site
Mizuho reiterated its Outperform rating and $195 price target
DateOct 27, 2026 FirmBMO Capital Markets RatingOutperform · maintains Targetat $95 · $192 +102% Horizonby Oct 2027 StatusOpen

Entry price $95, the close nearest Oct 27, 2026, when the target was reported; the target is +102% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 27, 2027.

Source H.C. Wainwright reiterates Insmed stock rating on pipeline progress Investing.com · Oct 27, 2026 · opens the publisher's site
BMO Capital maintained an Outperform rating with a $192 price target
DateOct 27, 2026 FirmUBS RatingBuy · reiterates Targetat $95 · $172 +81% Horizonby Oct 2027 StatusOpen

Entry price $95, the close nearest Oct 27, 2026, when the target was reported; the target is +81% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 27, 2027.

Source H.C. Wainwright reiterates Insmed stock rating on pipeline progress Investing.com · Oct 27, 2026 · opens the publisher's site
UBS also reiterated its Buy rating, setting a price target of $172
DateOct 27, 2026 FirmBank of America RatingBuy · maintains Targetat $95 · $207 +118% Horizonby Oct 2027 StatusOpen

Entry price $95, the close nearest Oct 27, 2026, when the target was reported; the target is +118% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 27, 2027.

Source H.C. Wainwright reiterates Insmed stock rating on pipeline progress Investing.com · Oct 27, 2026 · opens the publisher's site
BofA Securities adjusted its price target for Insmed to $207, maintaining a Buy rating
DateOct 27, 2026 FirmH.C. Wainwright RatingBuy · reiterates Targetat $95 · $220 +132% Horizonby Oct 2027 StatusOpen

Entry price $95, the close nearest Oct 27, 2026, when the target was reported; the target is +132% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 27, 2027.

Source H.C. Wainwright reiterates Insmed stock rating on pipeline progress Investing.com · Oct 27, 2026 · opens the publisher's site
H.C. Wainwright reiterated a Buy rating and $220.00 price target on Insmed
DateSep 24, 2026 FirmGoldman Sachs RatingBuy · initiates Targetat $122 · $188 +55% Horizonby Sep 2027 StatusOpen

Entry price $122, the close nearest Sep 24, 2026, when the target was reported; the target is +55% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Sep 2027.

Scoring Open: judged on the close on Sep 24, 2027.

Source Goldman Sachs initiates Insmed stock coverage with buy rating, $188 target Investing.com · Sep 24, 2026 · opens the publisher's site
with a buy rating and a price target of $188.00, according to a research note released Wednesday.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Insmed revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$606.4M−$335.2M−$1.28BFY2016 revenue: $0FY2016 net income: −$176.3M'16FY2017 revenue: $0FY2017 net income: −$192.6M'17FY2018 revenue: $9.84MFY2018 net income: −$324.3M · Net margin −3297.2%'18FY2019 revenue: $136.5MFY2019 net income: −$254.3M · Net margin −186.4%'19FY2020 revenue: $164.4MFY2020 net income: −$294.1M · Net margin −178.9%'20FY2021 revenue: $188.5MFY2021 net income: −$434.7M · Net margin −230.6%'21FY2022 revenue: $245.4MFY2022 net income: −$481.5M · Net margin −196.3%'22FY2023 revenue: $305.2MFY2023 net income: −$749.6M · Net margin −245.6%'23FY2024 revenue: $363.7MFY2024 net income: −$913.8M · Net margin −251.2%'24FY2025 revenue: $606.4MFY2025 net income: −$1.28B · Net margin −210.5%'25−100%−50%0%FY2018 net margin: −3297.2% (off the scale, which stops at −100.0%)FY2019 net margin: −186.4% (off the scale, which stops at −100.0%)FY2020 net margin: −178.9% (off the scale, which stops at −100.0%)FY2021 net margin: −230.6% (off the scale, which stops at −100.0%)FY2022 net margin: −196.3% (off the scale, which stops at −100.0%)FY2023 net margin: −245.6% (off the scale, which stops at −100.0%)FY2024 net margin: −251.2% (off the scale, which stops at −100.0%)FY2025 net margin: −210.5% (off the scale, which stops at −100.0%)
Insmed annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$0$0$9.84M$136.5M$164.4M$188.5M$245.4M$305.2M$363.7M$606.4M
Growth (year over year)———+1287.6%+20.5%+14.6%+30.2%+24.4%+19.2%+66.7%
Gross profit$0$0$7.41M$112.3M$124.5M$144.3M$190.2M$239.6M$278.0M$483.5M
Gross margin——75.4%82.3%75.7%76.6%77.5%78.5%76.4%79.7%
Operating income−$173.4M−$188.9M−$307.3M−$235.2M−$265.2M−$375.1M−$457.3M−$709.6M−$878.3M−$1.25B
Operating margin——−3124.9%−172.4%−161.3%−199.0%−186.4%−232.5%−241.5%−205.6%
Net income−$176.3M−$192.6M−$324.3M−$254.3M−$294.1M−$434.7M−$481.5M−$749.6M−$913.8M−$1.28B
Net margin——−3297.2%−186.4%−178.9%−230.6%−196.3%−245.6%−251.2%−210.5%
EPS (diluted)−$2.85−$2.89−$4.22−$3.01−$3.01−$3.88−$3.91−$5.34−$5.57−$6.42
Balance sheet
Cash and equivalents$162.6M$381.2M$495.1M$487.4M$532.8M$716.8M$1.07B$482.4M$555.0M$510.4M
Total assets$238.0M$462.0M$604.6M$742.3M$796.2M$1.24B$1.66B$1.33B$2.03B$2.26B
Total liabilities$83.5M$101.0M$396.3M$480.6M$520.3M$833.0M$1.57B$1.66B$1.74B$1.53B
Long-term debt$54.8M$55.6M$316.6M$335.9M$356.3M$566.6M$1.13B$1.16B$1.10B$541.0M
Shareholders' equity$154.5M$361.1M$208.3M$261.7M$275.9M$410.5M$88.0M−$331.9M$285.4M$739.0M
Cash flow
Operating cash flow−$146.7M−$159.6M−$258.0M−$250.6M−$219.3M−$363.3M−$400.4M−$536.2M−$683.9M−$935.0M
Capital expenditure$4.20M$3.00M$13.1M$42.3M$6.24M$7.29M$9.88M$13.3M$21.9M$32.6M
Free cash flow−$150.9M−$162.6M−$271.1M−$292.9M−$225.6M−$370.6M−$410.3M−$549.5M−$705.8M−$967.6M

From Insmed's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Insmed in the news

Nov 19, 2026 Benzinga ANT, INTU, AMD, INSM, GME: 5 Trending Stocks Today - Anthropic (NASDAQ:ANT)

About Insmed

Headquarters
Bridgewater, New Jersey From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →